Chronic rhinosinusitis: Future treatments review in JACI

Chronic rhinosinusitis (CRS) has a major clinical impact and affects 10% of the US population.

CRS presents with 2 major phenotypes:

- CRS with nasal polyps (CRSwNP)
- CRS without nasal polyps (CRSsNP)

Type 2 endotype (cytokines such as IL-4, IL-5, and IL-13; tissue eosinophilia; and local IgE production) comprises 80% to 90% of patients with CRSwNP and 30% to 50% of patients with CRSsNP in Western countries.

CRSwNP in Asia and CRSsNP have more endotypic heterogeneity, with significant subpopulations that have combinations of type 1 (IFN-γ and IL-12), type 2, and type 3 (IL-17 and IL-22) inflammation.

Read more in JACI here:
https://www.jacionline.org/article/S0091-6749(22)00760-6/fulltext